All In Biotech

Drug Trial Radar · NCT06143891

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of Belumosudil in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease (cGVHD)

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

Jan 23, 2024

Primary completion

Sep 29, 2028

Study completion Sep 29, 2028

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel, Phase 3, two-arm study for the treatment of newly diagnosed moderate or severe chronic GVHD. The study duration for a participant includes up to 4 weeks for screening; a treatment period until clinically meaningful cGVHD progression (defined as progression requiring addition of new systemic treatment for cGVHD), relapse/recurrence of the underlying disease, participant starts new systemic treatment for cGVHD or experiences an unacceptable toxicity, at the request of the participants or the investigators, or until the end of study is reached, whichever comes first; at least 30 days follow-up of adverse events (AEs) after the last dose until resolution or stabilization, if applicable; and long-term follow-up until death or study close-out, whichever comes first.

Conditions

  • Chronic Graft Versus Host Disease

Interventions

  • BelumosudilDrug

    Pharmaceutical form:Tablet-Route of administration:oral

  • PlaceboDrug

    Pharmaceutical form:Table-Route of administration:oral

  • PrednisoneDrug

    Pharmaceutical form:Tablet-Route of administration:oral

  • PrednisoloneDrug

    Pharmaceutical form:Tablet-Route of administration:oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-Free Survival (EFS)Time frame: Until the end of the study (up to 2.5 years since first patient in).

Locations

151 sites in 24 countries. Site status is shown where the registry gives one.

  • University of Arkansas for Medical Sciences-Site Number : 8400019

    Little Rock, Arkansas

  • City of Hope National Medical Center- Site Number : 8400001

    Duarte, California

  • University of California San Francisco - Parnassus Heights- Site Number : 8400035

    San Francisco, California

  • AdventHealth Orlando- Site Number : 8400023

    Orlando, Florida

  • The Hope Clinic of Emory University- Site Number : 8400020

    Decatur, Georgia

  • Northwestern University- Site Number : 8400017

    Chicago, Illinois

  • Indiana University Health University Hospital- Site Number : 8400006

    Indianapolis, Indiana

  • University of Kentucky Chandler Medical Center- Site Number : 8400024

    Lexington, Kentucky

  • Johns Hopkins Hospital- Site Number : 8400033

    Baltimore, Maryland

  • Dana Farber Cancer Institute Site Number : 8400005

    Boston, Massachusetts

  • Karmanos Cancer Institute - Detroit- Site Number : 8400013

    Detroit, Michigan

  • UNC Children's Hospital- Site Number : 8400025

    Chapel Hill, North Carolina

  • Atrium Health Wake Forest Baptist Medical Center - Winston-Salem - Medical Center Boulevard- Site Number : 8400007

    Winston-Salem, North Carolina

  • Oncology Hematology Care - Kenwood- Site Number : 8400030

    Cincinnati, Ohio

  • The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute- Site Number : 8400026

    Columbus, Ohio

  • Oregon Health and Science University- Site Number : 8400027

    Portland, Oregon

  • UPMC Hillman Cancer Center- Site Number : 8400008

    Pittsburgh, Pennsylvania

  • Sarah Cannon Research Institute Site Number : 8400003

    Nashville, Tennessee

  • St. David's South Austin Medical Center- Site Number : 8400002

    Austin, Texas

  • Texas Oncology - Dallas - Worth Street- Site Number : 8400010

    Dallas, Texas

  • Texas Transplant Institute - Methodist Hospital- Site Number : 8400037

    San Antonio, Texas

  • University of Virginia Comprehensive Cancer Center-Site Number : 8400031

    Charlottesville, Virginia

  • Fred Hutchinson Cancer Research Center- Site Number : 8400004

    Seattle, Washington

  • University of Wisconsin Carbone Cancer Center-Site Number : 8400029

    Madison, Wisconsin

  • Investigational Site Number : 0320005

    Buenos Aires, Argentina

  • Investigational Site Number : 0320003

    Buenos Aires, Argentina

  • Investigational Site Number : 0320001

    Buenos Aires, Argentina

  • Investigational Site Number : 0320002

    Buenos Aires, Argentina

  • Investigational Site Number : 0320004

    Córdoba, Argentina

  • Investigational Site Number : 0320006

    Pilar, Buenos Aires, Argentina

  • Investigational Site Number : 0360005

    Westmead, New South Wales, Australia

  • Investigational Site Number : 0360003

    Brisbane, Queensland, Australia

  • Investigational Site Number : 0360001

    Melbourne, Victoria, Australia

  • Investigational Site Number : 0360004

    Murdoch, Western Australia, Australia

  • Investigational Site Number : 0400003

    Graz, Austria

  • Investigational Site Number : 0400001

    Linz, Austria

  • Investigational Site Number : 0400004

    Vienna, Austria

  • Investigational Site Number : 0560006

    Bruges, Belgium

  • UZ Gent-Investigational Site Number : 0560003

    Ghent, Belgium

  • CHU de Liège-Investigational Site Number : 0560004

    Liège, Belgium

Showing 40 of 151 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.